[Pathophysiology-based phenotyping and clinical characterization of obesity]
1Department of Endocrinology and Metabolism, Peking University People's Hospital, Peking University Diabetes Center, Beijing Key Laboratory of Innovative Drug and Device Translation in Endocrine and Metabolic Diseases, Beijing 100044, China.
None:
Objective: To evaluate the applicability of a pathophysiology-based obesity phenotyping approach in Chinese patients with obesity and characterize the clinical features of different obesity phenotypes. Methods: In this cross-sectional study, patients with obesity (body mass index ≥28 kg/m2) were recruited from the obesity and weight management clinic of Peking University People's Hospital between December 2023 and November 2024. Data were collected regarding demographics, body composition, hunger perception [Visual Analogue Scale (VAS)], depressive status (Hospital Anxiety and Depression Scale), basal metabolic rate, and metabolic parameters. Using pre-established cut-off values derived from previous studies, participants were categorized into brain hunger, gastrointestinal hunger, emotional hunger, hypometabolic, or untyped phenotypes. The Kruskal-Wallis H test and other methods were used for comparisons among multiple groups, and the Bonferroni correction applied for multiple comparisons. Results: Among the 900 patients [mean age (34.9±8.3) years; 61.3% female, 552/900], the brain hunger phenotype (22.1%, 199/900) exhibited the highest 30-min VAS score [M (Q1, Q3), 33 (21, 43)], significantly exceeding that of the gastrointestinal hunger phenotype [19 (0, 30), all P<0.05]. The gastrointestinal hunger phenotype (43.9%, 395/900) demonstrated a significantly higher 2-hour VAS score [41 (30, 60)] than either the emotional hunger [20 (0, 41)] or hypometabolic [20 (0, 40)] phenotype (both P<0.05). The emotional hunger phenotype (34.1%, 307/900) had the highest depression score [8 (7, 9)], significantly exceeding those of the brain hunger [4 (2, 7)] and gastrointestinal hunger [4 (2, 7)] groups; its fasting C-peptide level [1.21 (0.95, 1.52) nmol/L] was significantly higher than those of the brain hunger [1.11 (0.84, 1.38) nmol/L] and gastrointestinal hunger [1.11 (0.85, 1.48) nmol/L] groups (all P<0.05). The hypometabolic phenotype (54.2%, 488/900) exhibited the lowest ratio of measured basal metabolic rate to predicted basal energy expenditure [82% (80%, 84%)], which was significantly lower than that of the brain hunger phenotype [86% (82%, 89%); all P<0.05]. This phenotype had the highest body mass index [34.22 (31.50, 37.38) kg/m2], which was significantly higher than that of the brain hunger phenotype [32.21 (30.20, 35.37) kg/m2; all P<0.05]. Furthermore, uric acid levels in the hypometabolic group [431 (370, 496) μmol/L] were significantly higher than those in the gastrointestinal hunger [405 (343, 473) μmol/L] and emotional hunger [413 (353, 476) μmol/L] phenotypes (both P<0.05); this group also had the highest body fat percentage [44.5% (39.3%, 48.5%)] and visceral fat level [20 (18, 20)] among all phenotypes (all P<0.05). Additionally, 16.3% (147/900) of patients remained untyped, while 49.0% (441/900) presented with multiple phenotypes. Conclusions: The pathophysiology-based phenotyping approach can identify subtypes with different clinical characteristics among Chinese patients with obesity. Each phenotype exhibits distinct characteristics in hunger regulation, emotional status, energy metabolism, and body composition.
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Drug Dosing: Obese Patients
Pharmacogenomics: Identification of New Drug Targets


